{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:45Z","timestamp":1793041965571,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573645"],"award-info":[{"award-number":["82573645"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82441028"],"award-info":[{"award-number":["82441028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["SHDC2025CCS018"],"award-info":[{"award-number":["SHDC2025CCS018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xcrm.2026.102659","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:15:27Z","timestamp":1773760527000},"page":"102659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Ying","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102659_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of Resistance to Antibody-Drug Conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102659_bib4","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1158\/1078-0432.CCR-15-1315","article-title":"New Strategies in Breast Cancer: Immunotherapy","volume":"22","author":"Pusztai","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102659_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102659_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102659_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102659_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of Immunotherapy in Triple-Negative Breast Cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.xcrm.2026.102659_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nbt.1614","article-title":"What is flux balance analysis?","volume":"28","author":"Orth","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102659_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-59745-525-1_3","article-title":"Flux balance analysis: interrogating genome-scale metabolic networks","volume":"500","author":"Oberhardt","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2026.102659_bib14","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1101\/gr.271205.120","article-title":"A graph neural network model to estimate cell-wise metabolic flux using single-cell RNA-seq data","volume":"31","author":"Alghamdi","year":"2021","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2026.102659_bib15","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1016\/j.cell.2021.05.045","article-title":"Metabolic modeling of single Th17 cells reveals regulators of autoimmunity","volume":"184","author":"Wagner","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib16","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","article-title":"Emerging therapies in cancer metabolism","volume":"35","author":"Xiao","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102659_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051307","article-title":"Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer","volume":"12","author":"Sebastian","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102659_bib18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102659_bib19","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102659_bib20","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","article-title":"B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer","volume":"179","author":"Hollern","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib22","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1038\/s41467-019-11738-0","article-title":"Metabolic landscape of the tumor microenvironment at single cell resolution","volume":"10","author":"Xiao","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102659_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41587-021-01020-4","article-title":"Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19","volume":"40","author":"Lee","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102659_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2018.05.005","article-title":"Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance","volume":"28","author":"Iwamoto","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102659_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13046-023-02647-8","article-title":"Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer","volume":"42","author":"Liu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102659_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102659_bib27","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1016\/j.molcel.2023.10.042","article-title":"SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation","volume":"83","author":"Zhang","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib28","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.cmet.2023.10.002","article-title":"Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer","volume":"35","author":"Li","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102659_bib29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.ccell.2022.08.012","article-title":"Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance","volume":"40","author":"Shi","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202206851","article-title":"Biomineralized Two-Enzyme Nanoparticles Regulate Tumor Glycometabolism Inducing Tumor Cell Pyroptosis and Robust Antitumor Immunotherapy","volume":"34","author":"Zhang","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xcrm.2026.102659_bib31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102659_bib32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3324\/haematol.2016.163030","article-title":"Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"102","author":"Noble","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102659_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102659_bib34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102659_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ccell.2024.05.006","article-title":"Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite","volume":"42","author":"Li","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib36","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ccell.2024.07.005","article-title":"Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers","volume":"42","author":"Sun","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib37","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.cmet.2023.09.009","article-title":"High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate","volume":"35","author":"Zhou","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102659_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccell.2020.09.004","article-title":"Immunometabolic Interplay in the Tumor Microenvironment","volume":"39","author":"Kaymak","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib39","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/onc.2016.370","article-title":"Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP\/PKA\/CREB\/glycolytic axis to confer tumor cells with multidrug resistance","volume":"36","author":"Yu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2026.102659_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","article-title":"Cancer SLC43A2 alters T cell methionine metabolism and histone methylation","volume":"585","author":"Bian","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102659_bib41","doi-asserted-by":"crossref","first-page":"77819","DOI":"10.18632\/oncotarget.20836","article-title":"Lactate stimulates CA IX expression in normoxic cancer cells","volume":"8","author":"Panisova","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2026.102659_bib42","first-page":"453","article-title":"Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release","volume":"39","author":"Goetze","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib43","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.cell.2024.04.002","article-title":"Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis","volume":"187","author":"Zong","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102659_bib45","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-10-2828","article-title":"Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-\u03baB\/IL-8 pathway that drives tumor angiogenesis","volume":"71","author":"V\u00e9gran","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102659_bib46","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/1566524016666160316153623","article-title":"VEGF Promotes Glycolysis in Pancreatic Cancer via HIF1\u03b1 Up-Regulation","volume":"16","author":"Shi","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102659_bib47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102659_bib48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102659_bib49","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.immuni.2025.03.002","article-title":"Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer","volume":"58","author":"Yu","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102659_bib50","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ccell.2025.03.015","article-title":"Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion","volume":"43","author":"Zhu","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib51","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.cmet.2025.08.009","article-title":"HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer","volume":"37","author":"Xiao","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102659_bib52","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41416-022-01848-w","article-title":"Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma","volume":"127","author":"Noble","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102659_bib53","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.3390\/pharmaceutics15122688","article-title":"Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer","volume":"15","author":"Silva","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.102659_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102659_bib55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/s41467-025-56392-x","article-title":"MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma","volume":"16","author":"Niveau","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102659_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006287","article-title":"Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies","volume":"11","author":"Lopez","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102659_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.32348","article-title":"Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack","volume":"77","author":"Fang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2026.102659_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814124","article-title":"Evaluating [(18)F]FDG and [(18)F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models","volume":"24","author":"Rainone","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102659_bib59","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1158\/2643-3230.BCD-22-0139","article-title":"HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion","volume":"4","author":"Toyoda","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102659_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216824","article-title":"Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming","volume":"589","author":"Yu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2026.102659_bib61","doi-asserted-by":"crossref","first-page":"11904","DOI":"10.1021\/acs.jmedchem.1c00448","article-title":"Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology","volume":"64","author":"Heinrich","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102659_bib62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/acschembio.2c00666","article-title":"Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit","volume":"18","author":"Kawatkar","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.xcrm.2026.102659_bib63","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/acs.jmedchem.2c01342","article-title":"Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology","volume":"66","author":"Goldberg","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102659_bib64","first-page":"63","article-title":"Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer","volume":"8","author":"Zhou","year":"2021","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.xcrm.2026.102659_bib65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib66","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102659_bib67","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102659_bib68","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102659_bib69","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102659_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:21:51Z","timestamp":1783095711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666379126000765"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102659","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102659"}}